SCHEMBL23997482

SCHEMBL23997482

NCc1ccc(Cn2c(=O)[nH]c3ccccc32)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.75
HTT P42858 2/20 0.75
MEN1 O00255 1/20 0.57
CYP1A2 P05177 1/20 0.57
KMT2A Q03164 1/20 0.57
APOBEC3G Q9HC16 1/20 0.54
HPGD P15428 4/20 0.53
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 2/20 0.53
PGR P06401 3/20 0.52
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 1/20 0.47
OPRM1 P35372 1/20 0.46
OPRK1 P41145 1/20 0.46
OPRL1 P41146 1/20 0.46
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30345072 1.00 LMNA (0.75) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL2762074 0.89 LMNA (0.81) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL4917013 0.86 LMNA (1.00) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997276 0.84 LMNA (0.75) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL31325551 0.84 LMNA (0.75) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL30336777 0.84 LMNA (0.65) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997374 0.84 LMNA (0.65) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL4920376 0.82 LMNA (0.76) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL4915141 0.81 LMNA (0.70) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997385 0.81 LMNA (0.69) LMNAHTTMEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 CN disclosed
WO-2021226003-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 LMNA 4017/4885HTT 4501/4885MEN1 1034/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 LMNA 4017/4885HTT 4501/4885MEN1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.